IMNM Insider Option Grant: 161K Shares to Chief Business Officer

Rhea-AI Filing Summary

Form 4 filing – Immunome, Inc. (IMNM) discloses that Chief Business Officer Kinney Horn received a new employee stock-option grant for 161,000 shares on 07/29/2025.

• Instrument: Non-qualified employee stock option giving the right to buy common stock at an exercise price of $10.60 per share.
• Vesting: 25 % vests on 07/29/2026; the remaining 75 % vests in equal monthly installments (1⁄36) thereafter, fully vesting by 07/29/2029.
• Expiration: 07/28/2035 (10-year term).
• Post-grant holdings: Horn now beneficially owns 161,000 derivative securities; no common shares were reported in Table I.

No shares were sold or disposed of, so the filing reflects compensation-related equity issuance rather than insider selling. The grant modestly increases the company’s fully-diluted share count and aligns the officer’s incentives with long-term shareholder value.

Positive

• Performance-aligned compensation: Options are struck at market price, incentivising value creation before reward.
• Retention mechanism: Four-year vesting schedule encourages the CBO to remain through 2029.

Negative

• Potential dilution: 161,000 new options add ≈0.6 % to fully-diluted share count.
• Equity overhang risk: Continued option issuance could pressure future EPS if exercised.

Insights

Corporate Governance Analyst

TL;DR: Large C-suite option grant; incentive-aligned, modest dilution, neutral-to-positive governance signal.

The 161 k option grant (≈0.6 % of IMNM’s ~26 M shares outstanding) is typical for a newly appointed CBO. Strike price of $10.60 sits at-or-above recent trading, creating performance-based upside. Ten-year term and four-year vesting encourage retention through 2029. As no shares were sold or hedged, the transaction is not a bearish liquidity event. Dilution impact is immaterial in the near-term but should be monitored as cumulative equity awards grow. Overall impact: neutral for valuation, slightly positive for incentive alignment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Kinney

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$10.6	07/29/2025		A		161,000		(1)	07/28/2035	Common Stock	161,000	$0	161,000	D

Explanation of Responses:

1. 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Immunome (IMNM) disclose in the latest Form 4?

The company granted Chief Business Officer Kinney Horn 161,000 stock options at a $10.60 strike price on 07/29/2025.

Does the filing involve insider selling of IMNM shares?

No. The transaction is an option grant; no shares were sold or disposed of.

When do the IMNM options vest and expire?

25 % vest on 07/29/2026; the rest vest monthly over 36 months. Expiration is 07/28/2035.

How many shares could be issued if all options are exercised?

Up to 161,000 new common shares, representing roughly 0.6 % of current shares outstanding.

What is the ownership form reported for the options?

They are held directly (D) by the reporting person.